指南与共识胸部肿瘤

恶性胸膜间皮瘤放射治疗的应用:美国国家癌症研究所胸部恶性肿瘤指导委员会、国际肺癌研究协会和间皮瘤应用研究基金会的专家意见

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
指南 / 共识 · J Thorac Oncol · 2019-05-22

由于恶性胸膜间皮瘤(MPM)罕见、临床表现多样且缺乏高级别数据,目前缺乏详细的放疗指南。2017年3月,美国国家癌症研究所、国际肺癌研究协会和间皮瘤应用研究基金会共同主办多学科专家会议,形成共识推荐。本文呈现三个场景的放疗共识建议:胸膜外全肺切除术前或术后的半胸放疗、保留肺手术后的辅助半胸放疗、以及针对局灶症状的姑息放疗,并讨论模拟技术、治疗体积、剂量分割和正常组织约束,评估粒子束治疗尤其是质子束治疗的作用。

要点

  • 共识推荐覆盖三个场景:胸膜外全肺切除术前或术后半胸放疗、保留肺手术后辅助半胸放疗、姑息放疗。
  • 讨论了适当的模拟技术、治疗体积、剂量分割方案和正常组织约束。
  • 评估了粒子束治疗尤其是质子束治疗在MPM中的作用。

核心结论

  • 本共识声明提供的推荐应作为未来开发MPM治疗临床试验的重要指南。

研究设计与样本

  • 2017年3月,由美国国家癌症研究所、国际肺癌研究协会和间皮瘤应用研究基金会共同主办多学科间皮瘤专家会议,形成详细的多学科共识指南。

主要发现

  • 共识推荐覆盖三个离散场景:胸膜外全肺切除术前或术后的半胸放疗、保留肺手术(即不进行全肺切除)后的辅助半胸放疗、以及针对疾病所致局灶症状的姑息放疗。
  • 讨论了适当的模拟技术、治疗体积、剂量分割方案和正常组织约束。
  • 评估了粒子束治疗尤其是质子束治疗在MPM中的作用。

关键数值与推荐

  • 推荐场景一:胸膜外全肺切除术前或术后使用半胸放疗。
  • 推荐场景二:保留肺手术后使用半胸放疗作为辅助治疗。
  • 推荐场景三:针对疾病所致局灶症状使用姑息放疗。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Detailed guidelines regarding the use of radiation therapy for malignant pleural mesothelioma (MPM) are currently lacking because of the rarity of the disease, the wide spectrum of clinical presentations, and the paucity of high-level data on individual treatment approaches. METHODS: In March 2017, a multidisciplinary meeting of mesothelioma experts was cosponsored by the U.S. National Cancer Institute, International Association for the Study of Lung Cancer Research, and Mesothelioma Applied Research Foundation. Among the outcomes of this conference was the foundation of detailed, multidisciplinary consensus guidelines. RESULTS: Here we present consensus recommendations on the use of radiation therapy for MPM in three discrete scenarios: (1) hemithoracic radiation therapy to be used before or after extrapleural pneumonectomy; (2) hemithoracic radiation to be used as an adjuvant to lung-sparing procedures (i.e., without pneumonectomy); and (3) palliative radiation therapy for focal symptoms caused by the disease. We discuss appropriate simulation techniques, treatment volumes, dose fractionation regimens, and normal tissue constraints. We also assess the role of particle beam therapy, specifically, proton beam therapy, for MPM. CONCLUSION: The recommendations provided in this consensus statement should serve as important guidelines for developing future clinical trials of treatment approaches for MPM.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Gomez DR, Rimner A, Simone CB, et al. The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2019. PMID: 31125736. doi:10.1016/j.jtho.2019.03.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。